MARK FAMADOR: Open Payments
NPI 1184890436 · MARLTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$406 in 18 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $35 · 2025 $406
Food & beverage: $406
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $137 |
| Vanda Pharmaceuticals Inc. | 6 | $101 |
| Tris Pharma Inc | 3 | $52 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
Products named: VRAYLAR, FANAPT, Dyanavel XR, REXULTI, Qelbree, CAPLYTA, Jornay PM, Relexxii.
Industry payments across NJ — which companies pay providers there.
